FRANCE - Immutep seeks EUR 13m from European VCs

French biopharmaceutical company Immutep is seeking a further EUR 13m from European investors, in addition to the EUR 5m already received from its existing investors. In December 2004, Innoven Partenaires led a EUR 2.5m second round of funding in the start-up, alongside co-investor Equitis through its specialist biotech fund, H2I. The proceeds were used to take the company's lead product, IMP321, into phase I/II clinical trials. Exactly a year earlier, Innoven Partenaires had provided a EUR 2.5m first round of funding in the company.